LAST Preparedness: What 2026 AORN & ASA Guidelines Mean for Your ASC

The Case That Should Keep Every ASC Director Up at Night

Picture this: a 47-year-old woman, ASA II, presents to your Miami ASC for an abdominoplasty with liposuction. The plastic surgeon infiltrates 3.5 liters of tumescent solution — lidocaine 0.05% with epinephrine, totally within the commonly cited 35 mg/kg tumescent ceiling — and thirty minutes into the case she starts seizing. The anesthesia team freezes for six seconds. Someone runs to the crash cart. Nobody can remember where the lipid emulsion is. The CRNA on duty is a 1099 contractor who started two weeks ago and has never run a LAST drill at this facility.

That scenario is not hypothetical. In fifteen years of practice as a CRNA and running an anesthesia group in Miami, I have seen the near-misses. And I am writing this post today because two simultaneous 2026 guideline releases have fundamentally changed what 'prepared' actually means for ambulatory surgery centers — right as those centers are taking on more complex, higher-block-volume cases than ever before.

If you are a plastic surgeon, CRNA, or ASC administrator reading this, local anesthetic systemic toxicity (LAST) is no longer a theoretical hospital problem. It is an ASC readiness mandate. Let me explain why — and what you need to do about it.

What LAST Actually Is (And Why Clinicians Still Underestimate It)

Local anesthetic systemic toxicity is a rare but potentially life-threatening condition that occurs when plasma concentrations of a local anesthetic exceed toxic thresholds — whether from inadvertent intravascular injection, absolute overdose, or rapid absorption from highly vascularized tissues. The result is CNS excitation (ringing in the ears, perioral numbness, agitation, seizures) followed by cardiovascular collapse: dysrhythmia, conduction block, and cardiac arrest. Bupivacaine is the most notorious offender because of its high cardiotoxicity and its tenacious binding to cardiac sodium channels, but ropivacaine, lidocaine, and mepivacaine all carry dose-dependent risk. (StatPearls, Local Anesthetic Toxicity, 2025)

Here is what troubles me most: despite how widely local anesthetics are used every single day across thousands of ASCs, awareness of LAST and knowledge of its management remain broadly lacking. Local anesthetics are frequently — and incorrectly — thought to be without meaningful side effects or toxicity risk. That cognitive blind spot is exactly where a preventable death lives. (UpToDate, Local Anesthetic Systemic Toxicity, updated Feb 2026)

In the plastic surgery world specifically, the risk surfaces across multiple technique categories: tumescent anesthesia for liposuction, peri-incisional infiltration for abdominoplasty, TAP blocks or rectus sheath blocks for abdominal cases, pectoral nerve blocks for breast augmentation and mastopexy, and supraclavicular blocks for upper-extremity work. Each one is clinically valuable. Each one carries a LAST exposure window. And increasingly, they are being stacked — a pec block plus wound infiltration plus a postoperative local infusion catheter — in ways that compound cumulative dose exposure.

The 2026 Guideline Double-Whammy Your ASC Cannot Ignore

Two major publications dropped in early 2026 that, taken together, represent an inflection point for LAST preparedness.

First: The AORN 2026 Guidelines for Perioperative Practice. The 2026 edition features a substantially revised Local Anesthesia Safety guideline that incorporates new research specifically on LAST — including updated evidence on recognition, team response, and rescue protocols. AORN is now explicitly calling on perioperative teams to have structured preparedness and response steps in place, not just a vial of lipid emulsion sitting in a drawer somewhere. This is a direct accountability signal to ASC nursing directors, surgeons, and anesthesia providers alike. (AORN 2026 Guidelines for Perioperative Practice)

Second: The ASA's January 2026 Practice Guideline on Perioperative Pain Management (Joshi GP et al., Anesthesiology 2026;144:19-43) broadly expands the recommended use of local and regional analgesia — including fascial plane blocks — across cardiothoracic surgeries, mastectomy, and abdominal procedures. This is the ASA's first procedure-specific guideline of this scope, and it is going to meaningfully increase local anesthetic exposure volumes at ASCs that perform these cases. More blocks, more volume, more cumulative dose, more LAST exposure windows. (Joshi GP et al., Anesthesiology 2026;144:19-43)

Read those two together and the message is unambiguous: use regional analgesia more broadly, and be fully prepared for the toxicity consequences when you do. The guidelines are expanding the practice. Your ASC has to expand the safety infrastructure to match.

The Scale Problem: 109 Million Procedures, Leaner Teams, Tighter Margins

Here is the context that makes this urgent rather than merely theoretical. ASC procedure volume has grown from roughly 6 million per year in 2000 to approximately 70 million by 2023, and is projected to exceed 109 million procedures annually by 2033. That is an almost 20-fold increase in the span of three decades. (Anesthesiology Clinics, Outpatient Anesthesia in 2026)

At the same time, the teams responsible for managing those cases are under serious structural stress. The anesthesiology workforce faces a projected shortage of 6,300 physicians by 2036, and 56% of CRNAs are already reporting burnout. (Becker's ASC, 5 Forces Shaping Anesthesia in 2026) More than 80% of ASCs now rely on contractor-based anesthesia coverage — meaning the CRNA or anesthesiologist in your OR on any given Tuesday may have never run a LAST drill at your specific facility, may not know where your lipid emulsion kit is stored, and may not be familiar with your facility's emergency call chain. (Becker's ASC, 5 Anesthesia Staffing Models ASCs Are Adopting in 2026)

Now layer on the reimbursement squeeze. The 2026 ASC conversion factor is $56.322 versus $91.415 for hospital outpatient departments. That structural gap directly compresses the margin available for emergency preparedness investments — lipid rescue kits, simulation training, protocol development, staff education. The facilities that most need robust LAST infrastructure are often the ones least resourced to build it.

For private-practice plastic surgeons running cash-pay cosmetic cases — abdominoplasties billing $12,000 to $25,000, body contouring cases with significant tumescent volumes — a LAST event that results in a bad outcome does not just cost a patient's wellbeing. It collapses the entire financial model of the practice. A single litigation exposure in this space routinely exceeds the revenue from thirty to fifty cases. The math on preparedness investment is not close.

What Your LAST Protocol Must Actually Include in 2026

Based on current evidence and what the updated AORN and ASA guidelines are pointing toward, here is what I consider the non-negotiable components of an ASC-ready LAST protocol right now:

• Lipid emulsion rescue kit — staged, labeled, and immediately accessible. 20% lipid emulsion (Intralipid) is the cornerstone rescue therapy for LAST. (StatPearls, Local Anesthetic Toxicity) The kit should be in every OR where regional or local anesthesia is performed — not in a back storeroom. Dosing: initial bolus of 1.5 mL/kg IV over 2-3 minutes, followed by an infusion of 0.25 mL/kg/min, repeated bolus every 3-5 minutes for refractory cardiovascular collapse, up to a maximum cumulative dose of approximately 10-12 mL/kg. Every team member should know the location and the dose before the first case of the day.
• Pre-case dose calculation for every patient, every block. For tumescent anesthesia in liposuction, the commonly cited ceiling is 35 mg/kg of lidocaine with epinephrine — but that number comes from specific infiltration technique data, not from every patient and every tissue bed equally. Highly vascularized areas and patients with reduced hepatic clearance (certain medications, liver disease, low albumin) shift the toxicity threshold meaningfully. Document the calculated maximum dose in the record before you start infiltrating.
• A written cognitive aid posted in the OR. When LAST happens, it often happens fast, and cognitive load collapses. A laminated LAST recognition and response checklist — covering prodromal symptoms, seizure management (benzodiazepines first, avoid propofol for refractory LAST), lipid emulsion dosing, and CPR modification (avoid vasopressin, use reduced epinephrine doses) — needs to be physically present in the room. Not on a shared drive. On the wall.
• Mandatory LAST orientation for every contracted anesthesia provider. Given that 80%+ of ASCs are using contractor models, this is not optional. Before any provider delivers a block at your facility, they should complete your facility's LAST protocol review and confirm kit location. This takes fifteen minutes and could save a life.
• Simulation drills at least annually. Real response performance degrades without practice. A tabletop drill or in-situ simulation — even a simple one — meaningfully improves team performance during actual events. The AORN 2026 guideline update explicitly supports structured team preparedness steps.

At MyPreOp.ai, we have built preoperative screening workflows designed to meet criteria for Clinical Decision Support under the 21st Century Cures Act — including flagging patient-level risk factors that can affect local anesthetic metabolism and toxicity thresholds: hepatic impairment markers, relevant drug interactions (amiodarone, beta-blockers, and other agents that compound bupivacaine cardiotoxicity), and weight-based dosing alerts. It is not a substitute for your LAST protocol, but it is one layer of the preparedness stack that runs before the patient ever gets to your OR.

A Word on Tumescent Anesthesia and the Plastic Surgery Risk Profile

I want to speak directly to the plastic surgeons in the room for a moment, because your LAST risk profile is genuinely different from a general surgery ASC.

Tumescent liposuction involves infiltrating large volumes of dilute lidocaine into subcutaneous fat — a relatively low-vascularity tissue that permits higher cumulative doses than direct intramuscular or perineural injection. That is the pharmacokinetic rationale behind the 35 mg/kg guideline. But when you are combining tumescent infiltration with a separate nerve block — say, a TAP block for the abdominoplasty component of a combined case — you are now drawing from the same systemic concentration pool with two different agents, potentially at two different absorption rates. The 0.25% bupivacaine you used for the TAP block does not know about the 800 mg of tumescent lidocaine that preceded it.

The ASA's 2026 pain management guideline expands fascial plane block recommendations precisely because the evidence for their analgesic value is strong. (Joshi GP et al., Anesthesiology 2026;144:19-43) But broader adoption in the ASC setting means your team — surgeons, CRNAs, OR nurses — needs to be thinking in terms of cumulative systemic load, not just "is this dose safe for this block?"

In my own practice, we track total local anesthetic load across the case in real time. It adds thirty seconds of documentation and has already prompted me to reduce supplemental infiltration volume on two occasions when cumulative dose was climbing toward a range I was not comfortable with given the patient's weight and the vascularity of the operative field. That discipline is not onerous — it is just good CRNA practice, and the 2026 guideline environment makes it an expectation rather than a differentiator.

How MyPreOp.ai Supports Your LAST Preparedness Stack

Preoperative screening is one of the most underutilized levers in LAST risk mitigation — not because LAST is always predictable, but because patient-level risk stratification shapes your block selection, dosing ceiling, and monitoring intensity before the case ever starts.

MyPreOp.ai's clinical decision support workflows are designed to surface the patient factors that modify local anesthetic risk: CYP1A2 inhibitors that slow lidocaine metabolism, cardiac conduction abnormalities that amplify bupivacaine toxicity risk, low serum albumin that reduces protein binding and raises free drug concentration. Our validation study documents the clinical performance of these screening pathways in the ambulatory surgery setting. Think of it as the upstream layer of your LAST protocol — the one that happens before the patient is on the table, before the block needle is in your hand.

The 2026 AORN guideline update and the ASA's expanded regional analgesia recommendations are not going away. The practice of anesthesia in the ASC setting is going to involve more local anesthetic, administered by more variable teams, to more complex patients, at higher volumes. That is not a reason to pull back from evidence-based regional techniques — it is a reason to build the preparedness infrastructure that lets you deploy them safely.

The Bottom Line: Preparedness Is Now a Standard of Care

The 2026 guideline environment has done something useful: it has made the implicit explicit. AORN is telling perioperative teams what structured LAST preparedness looks like. The ASA is expanding the regional analgesia toolkit while implicitly raising the bar for toxicity readiness. And the structural realities of the ASC market — growing procedure volume, contractor-heavy staffing, compressed reimbursement — mean that the responsibility for building that readiness falls on facility leadership, not on the next contracted CRNA who walks in the door.

In fifteen years of anesthesia practice, I have never seen a clearer convergence of clinical expansion and safety obligation. The facilities that take LAST preparedness seriously right now — lipid emulsion staged and ready, dose calculations documented, cognitive aids posted, teams drilled — are the ones that will not make the news for the wrong reasons. And in a cash-pay plastic surgery practice where your reputation is your entire revenue stream, that is not a small thing.

Get your lipid emulsion kit out of the storeroom. Run a drill. Build the protocol. And use every tool available — including smarter preoperative screening — to know your patient's risk profile before you pick up the needle.